Single-Use Technologies for the Biologic Market Size, Share, Growth, And Industry Analysis By Type (Membrane Adsorber, Bioreactors, Disposable Mixing Systems, Tangential Flow Filtration, Tubing and Connectors, Depth Filtration, Buffer Containers, Waste Containers, Single-Use Technologies for the Biologic) By Application (Monoclonal Antibodies, Vaccines, Gene Therapy, Recombinant Proteins, Blood Derivatives) and Regional Forecast From 2026 To 2035

Last Updated: 26 October 2026
SKU ID: 21990515

Trending Insights

Report Icon 1

Global Leaders in Strategy and Innovation Rely on Our Expertise to Seize Growth Opportunities

Report Icon 2

Our Research is the Cornerstone of 1000 Firms to Stay in the Lead

Report Icon 3

1000 Top Companies Partner with Us to Explore Fresh Revenue Channels

SINGLE-USE TECHNOLOGIES FOR THE BIOLOGIC MARKET OVERVIEW

The single-use technologies for the biologic market globally is expected to be valued at USD 7.02 Billion in 2026. It is forecasted to increase to USD 16.41 Billion by 2035. This reflects a compound annual growth rate CAGR of 9.9% between 2026 to 2035.

I need the full data tables, segment breakdown, and competitive landscape for detailed regional analysis and revenue estimates.

Download Free Sample

The single-use technologies for the biologic market covers disposable bioreactors, mixing systems, filtration assemblies, tubing, connectors, and storage containers that replace stainless-steel equipment in biologics manufacturing. Biopharmaceutical producers adopt these systems to shorten changeover time, lower cross-contamination risk, and reduce water and cleaning chemical use. Bioreactors hold the largest type share at 26%, while monoclonal antibodies account for 46% of application demand. Closed processing, pre-sterilized flow paths, and modular facility design make single-use technologies a core part of clinical and commercial production for contract manufacturers and emerging cell and gene therapy developers. Growing biologics pipelines further strengthen worldwide adoption momentum.

The United States remains the most influential national market for single-use technologies, supported by a dense cluster of biologics developers, contract manufacturers, and leading bioprocess equipment suppliers. Domestic demand is shaped by a deep monoclonal antibody pipeline, expanding cell and gene therapy programs, and strong investment in flexible manufacturing capacity. Regulatory clarity from the Food and Drug Administration on extractables and leachables supports supplier qualification and user confidence. Biotechnology hubs in Massachusetts, North Carolina, and California continue to adopt closed, disposable platforms to speed clinical supply. Onshoring of pharmaceutical production further encourages modular facility upgrades built on single-use infrastructure.

KEY FINDINGS

  • Type Leadership: Bioreactors lead with a 26% share, driven by scalable stainless-steel replacement, lower contamination risk, and faster batch changeover in biologics plants.
  • Application Leadership: Monoclonal antibodies hold a 46% share, supported by expanding antibody pipelines, multiproduct facility needs, and rising demand for flexible biologics manufacturing capacity.
  • Key Company Landscape: Sartorius and Thermo Fisher Scientific lead through integrated bioreactor platforms, filtration portfolios, and global single-use manufacturing capacity, strengthening upstream and downstream workflows.
  • Leading Regional Market: North America leads with a 41% share, while Asia Pacific is the fastest-growing region, supported by biologics capacity expansion and contract manufacturing investment.
  • Key Trends: Single-use bioreactors now reach 5,000 liters, while automation and continuous processing accelerate adoption; extractables concerns and plastic waste remain key challenges.

Automation and digital integration are reshaping the single-use technologies for the biologic market, as manufacturers add in-line sensors, Raman spectroscopy, and artificial intelligence tools for real-time visibility into disposable bioreactors and downstream skids. Process intensification is another strong trend, as perfusion and continuous bioprocessing raise consumable use per batch and demand higher-capacity filters and closed fluid paths. Scale is advancing as well, with Thermo Fisher Scientific offering DynaDrive bioreactors that reach 5,000 liters, moving disposable platforms deeper into commercial production.

Downstream adoption is widening as single-use chromatography, membrane adsorbers, and tangential flow filtration replace fixed stainless-steel skids. Supplier consolidation continues, as Merck KGaA recently completed its acquisition of the JSR Life Sciences chromatography business, adding Protein A resin capabilities. Sustainability is gaining weight, with suppliers testing recyclable films and take-back programs to address plastic waste. Standardized extractables and leachables testing is improving user confidence and speeding supplier qualification. Cell and gene therapy developers are driving demand for compact, closed, and automated systems built for small patient-specific batches, and Sartorius launched its Eveo cell therapy platform to address this need. Together, these developments position disposable technologies as the default choice for new biologics manufacturing capacity across regions.

Global-Single-Use-Technologies-for-the-Biologic-Market-Share

ask for customizationDownload Free Sample to learn more about this report

SINGLE-USE TECHNOLOGIES FOR THE BIOLOGIC MARKET SEGMENTATION

By Type

Based on Type the global market can be categorized in to membrane adsorber, bioreactors, disposable mixing systems, tangential flow filtration, tubing and connectors, depth filtration, buffer containers, and waste containers.

  • Membrane Adsorber: Membrane adsorber holds a 10% share of the single-use technologies for the biologic market. These ready-to-use chromatography devices capture host cell proteins, residual DNA, and viruses through convective flow, which allows higher throughput than packed-bed columns. Manufacturers avoid column packing, cleaning validation, and long equilibration cycles, so membrane adsorbers suit polishing steps in monoclonal antibody production and viral vector purification. Disposable capsules also reduce buffer consumption and shorten turnaround between batches. Demand is rising in gene therapy workflows, where fast and gentle purification protects fragile vectors. Suppliers continue to improve ligand chemistry and binding capacity to widen use across downstream platforms.
  • Bioreactors: Bioreactors lead the type segmentation with a 26% share, making them the largest contributor to the single-use technologies for the biologic market. Pre-sterilized disposable vessels eliminate steam sterilization and cleaning validation, which cuts turnaround time and lowers cross-contamination risk. Scale has advanced significantly, with Sartorius offering Biostat platforms up to 2,000 liters and Thermo Fisher Scientific reaching 5,000 liters with DynaDrive. Perfusion and fed-batch processes both rely on these vessels, and integrated sensors support tighter control of oxygen transfer, pH, and temperature. Contract manufacturers favor them for multiproduct facilities because a single suite can switch products rapidly with limited downtime.
  • Disposable Mixing Systems: Disposable mixing systems account for a 15% share, supporting buffer preparation, media blending, and formulation of biologic drug products. Single-use mixers use pre-sterilized bags with integrated impellers, which removes cleaning cycles and prevents carryover between batches. Magnetic levitation and bottom-driven designs deliver gentle mixing that protects shear-sensitive proteins and viral particles. Manufacturers value the compact footprint, fast deployment, and ability to scale from laboratory volumes to commercial batches without rebuilding fixed tanks. Rising monoclonal antibody output increases buffer and media volumes, which keeps demand for disposable mixers steady. Integration with load cells and sensors also supports accurate dosing and traceable records in regulated plants.
  • Tangential Flow Filtration: Tangential flow filtration holds a 14% share and plays a central role in concentration and buffer exchange for biologics. Single-use cassettes and hollow fiber modules arrive pre-assembled and sterilized, which removes flushing, storage, and cleaning steps required by reusable membranes. Flexible assemblies support ultrafiltration and diafiltration of monoclonal antibodies, recombinant proteins, and vaccines with consistent yield. Automated single-use skids with disposable flow paths shorten changeover and limit validation effort. Demand is also growing in continuous manufacturing, where alternating tangential flow systems retain cells during perfusion. Suppliers focus on higher membrane capacity, low protein loss, and improved fouling resistance to support intensified processes.
  • Tubing and Connectors: Tubing and connectors represent a 13% share and form the sterile fluid pathways that link every unit operation in a closed process. Platinum-cured silicone tubing, thermoplastic elastomer lines, and genderless aseptic connectors allow operators to join sterile paths without a laminar flow hood. Sterile welders and tube sealers further support closed transfers during harvest, filtration, and filling. Because every process uses multiple assemblies, consumption is high and recurring, which makes this segment a stable source of demand. Custom pre-assembled manifolds reduce operator errors and speed up setup. Particulate control, low extractables, and leak testing remain essential for regulatory acceptance.
  • Depth Filtration: Depth filtration holds a 9% share and is widely used for harvest clarification, where it removes cells, debris, and colloids before chromatography. Single-use capsules and pods eliminate housing cleaning and reduce setup time, while multilayer media provide high loading capacity for dense cell cultures. As intensified processes raise cell densities, harvest streams carry more particulates, which increases demand for higher capacity filter media. Primary clarification protects downstream resins and membranes from fouling and extends their working life. Closed capsule formats also reduce operator exposure and contamination risk. Suppliers are developing synthetic media that offer low extractables and consistent performance across antibody and vaccine harvests.
  • Buffer Containers: Buffer containers account for an 8% share, providing flexible storage and transfer of process buffers, media, and intermediates. Pre-sterilized bags in 2D and 3D formats replace large stainless-steel hold tanks, freeing cleanroom floor space and removing cleaning and sanitization steps. Multilayer films with low extractables and strong gas barrier properties protect product quality during storage and shipping. Standardized bag sizes and custom tubing sets allow rapid connection to mixers and chromatography skids. As downstream operations use larger buffer volumes for each batch, demand grows steadily. Ready-to-use buffer bags are also gaining attention among facilities that want to limit on-site preparation workload.
  • Waste Containers: Waste containers hold a 5% share and represent the smallest type segment, yet they provide important safety and compliance benefits. Single-use waste bags and containment systems collect spent media, wash fluids, and process effluents from bioreactors and chromatography skids in a closed manner. Their use reduces operator exposure to biohazardous material and avoids tank cleaning and neutralization steps. Facilities running cell therapy and viral vector processes prefer disposable waste handling to meet strict biosafety rules. Rigid tote and bag-in-drum formats support easy transport to inactivation systems. Growth is moderate because volume per batch is small, but adoption rises alongside the broader shift to closed facilities.

By Application

By Application the global market can be categorized in to monoclonal antibodies, vaccines, gene therapy, recombinant proteins, and blood derivatives.

  • Monoclonal Antibodies: Monoclonal antibodies lead application demand with a 46% share of the single-use technologies for the biologic market. Antibody production relies on high-titer cell culture, multi-step purification, and tight contamination control, all of which align with disposable bioreactors, depth filters, and membrane adsorbers. Large pipelines in oncology and autoimmune disease keep clinical and commercial volumes high, and biosimilar developers favor single-use suites for fast and cost-efficient facility setup. Platform processes allow users to standardize disposable assemblies across many antibody candidates, which shortens technology transfer to contract manufacturers. Perfusion and intensified fed-batch formats increase consumable usage further, supporting steady growth in this segment.
  • Vaccines: Vaccines hold a 20% share, supported by large-volume production needs and the requirement for rapid, flexible capacity. Single-use bioreactors and mixers allow manufacturers to switch between viral and protein-based vaccine platforms with limited cleaning validation, which helps with seasonal and outbreak-driven demand. Closed disposable systems lower exposure risk when handling live viruses and cell lines. Disposable depth filters, tangential flow filtration, and tubing assemblies support clarification, concentration, and sterile transfer across the process. Pandemic preparedness programs and regional manufacturing initiatives in emerging economies continue to promote modular facilities that rely on disposable technologies for faster commissioning and technology transfer.
  • Gene Therapy: Gene therapy accounts for a 12% share and is among the fastest-evolving applications for disposable technologies. Viral vector production, including adeno-associated virus and lentivirus, requires small to mid-scale batches, strict containment, and patient-specific changeover, which suit single-use bioreactors and closed fluid paths. Membrane adsorbers and tangential flow filtration support gentle purification of fragile vectors. Disposable systems remove cross-contamination risk between products and reduce validation effort for developers with several candidates in early trials. Rising approvals of gene-based treatments and growing investment from specialist contract manufacturers are expanding demand for scalable suspension bioreactors and ready-to-use assemblies designed for vector processes.
  • Recombinant Proteins: Recombinant proteins represent a 15% share, covering hormones, enzymes, cytokines, and therapeutic proteins produced in mammalian, microbial, and yeast systems. Single-use bioreactors, mixers, and filtration assemblies allow manufacturers to run flexible campaigns for products with modest volumes, such as insulin analogs, enzyme replacement therapies, and growth factors. Disposable flow paths cut cleaning cycles and support fast changeover between products in multipurpose plants. Demand also comes from biosimilar insulin programs and orphan biologics, where small batches and low capital investment matter. Suppliers offer scalable platforms that move from process development to clinical supply without redesigning equipment, which supports consistent adoption in this segment.
  • Blood Derivatives: Blood derivatives hold a 7% share, covering albumin, immunoglobulins, and clotting factors fractionated from human plasma or produced through recombinant routes. Adoption is more gradual because traditional plasma fractionation uses large stainless-steel installations, yet disposable bags, tubing, filters, and mixers are increasingly used in buffer handling, filtration, and final formulation. Closed single-use assemblies help limit contamination and viral safety risks in products derived from human sources. Rising demand for immunoglobulin therapies and recombinant clotting factors encourages manufacturers to add flexible disposable suites beside existing fractionation lines. Quality-focused users value traceable consumables with validated extractables data to support regulatory submissions.

MARKET DYNAMICS

Driving Factor

Rising demand for monoclonal antibodies and flexible biologics manufacturing.

Growing pipelines of antibody-based and other biologic drugs push manufacturers to build capacity quickly without the long lead times of stainless-steel plants. Monoclonal antibodies account for 46% of application demand, and each program requires bioreactors, filters, mixers, and sterile assemblies that single-use systems supply in ready-to-use form. Disposable platforms cut cleaning validation, lower water and chemical consumption, and shorten changeover, which helps multiproduct facilities and contract manufacturers handle many candidates in parallel. Faster technology transfer and lower upfront capital also make it easier for small and mid-sized biotechnology companies to enter commercial production, widening the customer base for disposable technologies.

Drivers impact analysis*

Market drivers CAGR impact (%) 2026-2028 2029-2031 2032-2035
Increasing demand for biologics and monoclonal antibody manufacturing +3.50% High High High
Growing adoption of single-use bioreactors and disposable bioprocessing systems +3.00% High High High
Expansion of contract development and manufacturing organizations +2.50% High High High
Rising demand for flexible manufacturing and reduced cross-contamination risks +2.00% Medium High High
Advancements in disposable filtration, tubing, and bioprocess automation +1.50% Medium High High
Others +0.50% Low Medium Medium

Restraining Factor

Extractables and leachables concerns and limited scale for large commercial batches.

Plastic films, tubing, and filter components can release extractables and leachables into process streams, so users must complete detailed risk assessments and supplier qualification before adopting new assemblies. These requirements lengthen validation timelines and raise testing costs, particularly for sensitive therapies. Scale is another limitation, as 5,000 liters is currently the largest single-use bioreactor volume available, which keeps stainless steel preferred for very high-volume products. Dependence on a small group of film, resin, and component suppliers also exposes users to supply interruptions and price changes, which can slow decisions among manufacturers that prioritize supply security and long-term cost predictability.

Restraints impact analysis*

Market restraints CAGR impact (%) 2026-2028 2029-2031 2032-2035
Environmental concerns regarding plastic waste from disposable bioprocessing systems -1.30% High High High
Supply chain dependence and high recurring costs of single-use consumables -1.00% High Medium Medium
Technical limitations in large-scale bioprocessing and extractables and leachables validation -0.60% Medium Medium Low
Others -0.20% Low Low Low
Market Growth Icon

Growth in cell and gene therapy and personalized medicine.

Opportunity

Personalized treatments are produced in small, patient-specific batches that require rapid changeover, strict containment, and minimal facility footprint, which matches the strengths of disposable systems. Developers of viral vectors, cell therapies, and nucleic acid medicines increasingly choose closed, automated single-use platforms that integrate several process steps in one controlled environment. Suppliers that offer compact bioreactors, ready-to-use assemblies, and digital process control can capture demand from academic centers, startups, and specialist contract manufacturers. Regional manufacturing programs in emerging markets also create room for modular, pre-validated facilities built around disposable equipment, supporting new supplier partnerships and service offerings.

Market Growth Icon

Plastic waste and sustainability pressure.

Challenge

Disposable bags, tubing, and filters generate significant volumes of plastic waste, and many sites still depend on incineration or landfill because biohazard rules limit recycling options. Pharmaceutical companies now track environmental targets, so suppliers face pressure to prove lifecycle benefits through water, energy, and carbon comparisons with stainless-steel operations. Developing recyclable films, take-back programs, and lower-carbon materials requires investment and regulatory alignment, while any material change must preserve strength, sterility, and low extractables. Balancing environmental goals with quality, cost, and supply reliability remains a complex task for both users and manufacturers, and it can influence procurement choices and long-term technology roadmaps.

SINGLE-USE TECHNOLOGIES FOR THE BIOLOGIC MARKET REGIONAL INSIGHTS

  • North America

North America leads the single-use technologies for the biologic market with a 41% share. The region benefits from a deep base of biologics developers, contract development and manufacturing organizations, and leading equipment suppliers. Thermo Fisher Scientific operates single-use manufacturing sites in Utah, Pennsylvania, and Tennessee, which strengthens regional supply security. Monoclonal antibodies, which hold 46% of global application demand, anchor consumption across clinical and commercial plants. Regulatory guidance from the Food and Drug Administration on extractables and leachables supports confident adoption of disposable assemblies. Strong venture funding, onshoring programs, and growing cell and gene therapy activity in Massachusetts, North Carolina, and California keep demand for bioreactors, filtration systems, and sterile connectors high. Canada adds steady demand through vaccine and advanced therapy projects.

  • Europe

Europe holds a 28% share, supported by a mature pharmaceutical base and the headquarters of major suppliers. Sartorius in Germany and Novasep in France anchor the regional supplier landscape, while Merck KGaA and Thermo Fisher Scientific maintain significant European operations, including a single-use site in the United Kingdom. Bioreactors, which lead the type segmentation with a 26% share, are widely installed in antibody and vaccine plants in Germany, Switzerland, Ireland, Denmark, and Belgium. European Medicines Agency guidance and strong quality culture encourage supplier qualification and standardized testing of disposable components. Sustainability targets are also shaping procurement, as regional manufacturers evaluate recyclable films and lower-impact assemblies. Contract manufacturers continue to add flexible suites for biosimilars and advanced therapies.

  • Asia Pacific

Asia Pacific accounts for a 21% share and is the fastest-growing region. Contract manufacturers in Singapore, South Korea, China, India, and Japan are adding biologics capacity, and governments support local biotechnology through funding and manufacturing incentives. AGC Biologics is installing 2 DynaDrive bioreactors of 5,000 liters at its Yokohama facility, showing that large disposable platforms are entering commercial production in the region. Thermo Fisher Scientific has expanded single-use capacity in Singapore and Suzhou, and has added a bioprocess design center in India. Vaccines, which hold a 20% global share, remain a major regional demand driver, alongside rising antibody output and biosimilar development. Growing local supplier participation is also improving availability and shortening delivery times for disposable assemblies.

  • Middle East & Africa

Middle East and Africa holds a 4% share, reflecting an early stage of biologics manufacturing but rising strategic interest. Saudi Arabia, the United Arab Emirates, Egypt, and South Africa are encouraging local pharmaceutical and vaccine production to reduce import dependence and strengthen health security. Modular facilities built around single-use bioreactors, mixers, and filtration assemblies suit these programs because they need less infrastructure and allow faster commissioning than stainless-steel plants. Vaccines, which account for 20% of global application demand, are a leading focus, supported by technology transfer partnerships with international manufacturers. Training programs and regulatory development are gradually improving the ecosystem. Imports of disposable components remain dominant, creating opportunities for global suppliers to provide service, validation support, and local distribution.

  • Rest of the World

The Rest of the World holds a 6% share, led by Latin America, where Brazil, Argentina, and Mexico are expanding biologics and vaccine capacity. Public health programs and local production partnerships encourage investment in flexible facilities, and disposable technologies reduce the capital burden of new plants. Recombinant proteins, which represent 15% of global application demand, are important in this region through insulin, enzyme, and growth factor programs. Plasma fractionation initiatives also create demand for tubing, bags, and filtration components in blood derivative processing, a segment with a 7% global share. Currency movements and import logistics can affect purchasing decisions, so suppliers with regional warehousing and technical support have an advantage. Gradual regulatory harmonization is supporting broader technology adoption.

KEY INDUSTRY PLAYERS

The single-use technologies for the biologic market is led by global vendors that offer integrated portfolios across bioreactors, mixing, filtration, chromatography, and sterile connection. Established suppliers compete through scale, validated component libraries, automation, and global manufacturing networks, while emerging players focus on specialized filtration media, sensors, and compact systems for advanced therapies. Competitive strategies include acquisitions, capacity expansion, long-term supply agreements, and co-development projects with biopharma companies and contract manufacturers. Positioning increasingly depends on end-to-end workflow support, extractables data quality, and digital integration, as customers prefer partners that reduce validation effort, secure supply continuity, and help scale processes from development to commercial production.

List of Top Single-Use Technologies for the Biologic Companies

  • Thermo Fisher Scientific
  • Applikon Biotechnology
  • GE Healthcare
  • Pall
  • BioPure Technology
  • Sartorius
  • Novasep
  • L. Gore and Associates
  • EMD Millipore
  • DowDuPont

LEADER INSIGHTS

  • Sartorius: Dr. Michael Grosse, Chief Executive Officer of Sartorius, emphasized that robust biopharmaceutical customer activity and recovering demand for bioprocessing equipment are creating opportunities for sustained industry expansion. His comments highlight how growing drug development pipelines, recurring demand for consumables, and increasing adoption of advanced manufacturing technologies are supporting the long-term outlook for single-use bioprocessing solutions. (Published: October 22, 2026 | Source: https://www.sartorius.com/)
  • Thermo Fisher Scientific: Marc N. Casper, Chairman and Chief Executive Officer of Thermo Fisher Scientific, emphasized that strengthening customer activity across life sciences markets is supporting continued investment in advanced biopharmaceutical manufacturing capabilities. His comments highlight opportunities to accelerate drug development, improve manufacturing efficiency, and expand collaborative bioprocessing infrastructure to meet evolving pharmaceutical and biotechnology industry requirements. (Published: July 23, 2026 | Source: https://www.thermofisher.com/)
  • Sartorius Stedim Biotech: René Fáber, Chief Executive Officer of Sartorius Stedim Biotech, emphasized that increasing demand for manufacturing efficiency, scalability, and reliability is accelerating innovation across biopharmaceutical production. His comments highlight opportunities to expand single-use technologies, process intensification, and advanced analytical solutions as biologics manufacturers pursue more flexible production systems and improved commercial manufacturing performance. (Published: March 17, 2026 | Source: https://www.sartorius.com/)

INVESTMENT ANALYSIS AND OPPORTUNITIES

Investment in the single-use technologies for the biologic market is focused on manufacturing capacity, downstream purification, and advanced therapy platforms. Suppliers are expanding film, bag, and filter production to secure supply, while acquisitions such as Merck KGaA’s recent purchase of the JSR Life Sciences chromatography business strengthen downstream portfolios. Contract manufacturers are equally active, with AGC Biologics installing 2 bioreactors of 5,000 liters in Yokohama. Opportunities are strongest in membrane adsorbers, automated tangential flow filtration, and closed systems for gene therapy. Investors also see potential in regional manufacturing programs across Asia Pacific, the Middle East, and Latin America, where modular disposable facilities reduce capital requirements.

NEW PRODUCT DEVELOPMENT

Innovation in the single-use technologies for the biologic market centers on scalability, integration, and process control. Thermo Fisher Scientific introduced a 5 liter benchtop DynaDrive bioreactor that keeps one design lineage from development to 5,000 liters, and its literature reports up to 190% higher oxygen mass transfer than legacy single-use designs. Sartorius launched the Eveo cell therapy platform, a closed system combining cell selection, activation, gene modification, expansion, and formulation. Suppliers are also developing sensors with improved accuracy, Raman-enabled monitoring, recyclable film structures, and higher-capacity depth filters. Pre-assembled and pre-validated flow paths are reducing setup errors and helping users move from pilot to commercial production faster.

RECENT DEVELOPMENTS

  • January 2026 – Cytiva expanded its Xcellerex X-platform bioreactor portfolio with 500 L and 2,000 L formats, helping biologics manufacturers improve yields while reducing manufacturing time and cost.
  • January 2026 – Thermo Fisher Scientific reported expanded bioprocess design centers in Asia, including a new India site, supporting process development and scale-up for single-use biologics bioprocessing customers.
  • March 2026 – Sartorius launched the Eveo cell therapy platform, a closed system integrating cell selection, activation, gene modification, expansion, and formulation to streamline manufacturing for therapy developers.
  • April 2026 – Merck KGaA completed the acquisition of JSR Life Sciences’ chromatography business, adding Amsphere Protein A resins to strengthen downstream purification capabilities for monoclonal antibody manufacturers.
  • July 2026 – Bio-Process Systems Alliance hosted its International Single-Use Summit in Boston, convening suppliers and biopharma end users to address automation, artificial intelligence, and manufacturing flexibility needs.

REPORT COVERAGE

This report covers the global single-use technologies for the biologic market across 8 product types, 5 applications, and 5 regional groups, with a long-term forecast horizon. It evaluates segment shares, technology trends, drivers, restraints, opportunities, and challenges, and profiles 10 key companies through their portfolios, strategies, and market positioning. Regional analysis examines North America, Europe, Asia Pacific, Middle East and Africa, and the Rest of the World, with shares. The report also reviews investment activity, new product development, and recent developments, giving manufacturers, suppliers, investors, and strategy teams a structured view of demand, competition, and growth areas.

Single-Use Technologies for the Biologic Market Report Scope & Segmentation

Attributes Details

Market Size Value In

US$ 7.02 Billion in 2026

Market Size Value By

US$ 16.41 Billion by 2035

Growth Rate

CAGR of 9.9% from 2026 to 2035

Forecast Period

2026 - 2035

Base Year

2025

Historical Data Available

Yes

Regional Scope

Global

Segments Covered

By Type

  • Membrane Adsorber
  • Bioreactors
  • Disposable Mixing Systems
  • Tangential Flow Filtration
  • Tubing and Connectors
  • Depth Filtration
  • Buffer Containers
  • Waste Containers

By Application

  • Monoclonal Antibodies
  • Vaccines
  • Gene Therapy
  • Recombinant Proteins

FAQs

Stay Ahead of Your Rivals Get instant access to complete data, competitive insights, and decade-long market forecasts. Download FREE Sample